PT2639229E - Derivado de tiazole e sua utilização como inibidor de vap-1 - Google Patents

Derivado de tiazole e sua utilização como inibidor de vap-1 Download PDF

Info

Publication number
PT2639229E
PT2639229E PT131721268T PT13172126T PT2639229E PT 2639229 E PT2639229 E PT 2639229E PT 131721268 T PT131721268 T PT 131721268T PT 13172126 T PT13172126 T PT 13172126T PT 2639229 E PT2639229 E PT 2639229E
Authority
PT
Portugal
Prior art keywords
vap
inhibitor
thiazole derivative
thiazole
derivative
Prior art date
Application number
PT131721268T
Other languages
English (en)
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of PT2639229E publication Critical patent/PT2639229E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT131721268T 2008-01-31 2009-01-30 Derivado de tiazole e sua utilização como inibidor de vap-1 PT2639229E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008021588 2008-01-31

Publications (1)

Publication Number Publication Date
PT2639229E true PT2639229E (pt) 2015-02-04

Family

ID=40546096

Family Applications (1)

Application Number Title Priority Date Filing Date
PT131721268T PT2639229E (pt) 2008-01-31 2009-01-30 Derivado de tiazole e sua utilização como inibidor de vap-1

Country Status (18)

Country Link
US (1) US8507690B2 (pt)
EP (4) EP2252604B1 (pt)
JP (1) JP5415430B2 (pt)
KR (1) KR101622414B1 (pt)
CN (1) CN101932568B (pt)
AR (1) AR070336A1 (pt)
AU (1) AU2009209885B2 (pt)
BR (1) BRPI0906352A2 (pt)
CA (1) CA2712962C (pt)
DK (1) DK2639229T3 (pt)
ES (2) ES2527014T3 (pt)
HK (2) HK1152293A1 (pt)
MX (1) MX2010008460A (pt)
NZ (1) NZ587205A (pt)
PT (1) PT2639229E (pt)
RU (1) RU2496776C9 (pt)
TW (1) TWI437986B (pt)
WO (1) WO2009096609A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
US8802666B2 (en) * 2009-12-21 2014-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibitors of cyclophilins and uses thereof
TWI594764B (zh) * 2010-04-12 2017-08-11 生化治療公司 治療用途
ES2628850T3 (es) * 2011-03-15 2017-08-04 Astellas Pharma Inc. Compuesto de guanidina
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018080113A (ja) 2015-05-27 2018-05-24 株式会社アールテック・ウエノ 脳梗塞処置剤
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
FR3037954B1 (fr) * 2015-06-24 2017-08-11 Michelin & Cie Procede de synthese de molecules azo-dicarbonylees porteuses de groupes associatifs
AU2016366635A1 (en) 2015-12-07 2018-06-21 Benevolentai Cambridge Limited VAP-1 inhibitors for treating pain
WO2018097294A1 (ja) * 2016-11-28 2018-05-31 帝人ファーマ株式会社 糖尿病性腎症の治療薬または予防薬
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
CA3139104A1 (en) * 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Thiosemicarbazates and uses thereof
EP3965792A4 (en) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research HMGB1 ANTAGONIST
SE544131C2 (en) * 2020-03-16 2022-01-04 Pvac Medical Tech Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1181871B (it) 1985-04-01 1987-09-30 Consiglio Nazionale Ricerche Inibitori selettivi delle benzilamminossidasi rispetto ad altre amminossidasi
TW205041B (pt) * 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
AU4055593A (en) 1992-05-15 1993-12-13 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
RU2003103286A (ru) 2000-07-05 2004-08-20 Байотай Терапис Корпорейшн (Fi) Ингибиторы медьсодержащих аминооксидаз
ES2168084B1 (es) 2000-11-07 2003-11-16 Univ Barcelona Combinacion de aminas y compuestos de vanadio (iv) (v) para el tratatamiento y/o la prevencion de la diabetes mellitus.
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
CN100491361C (zh) * 2003-01-27 2009-05-27 安斯泰来制药有限公司 噻唑衍生物及其作为vap-1抑制剂的用途
CA2514573A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
US20060229346A1 (en) * 2003-03-31 2006-10-12 Sucampo Ag Method for treating vascular hyperpermeable disease
CN1933833B (zh) * 2004-03-18 2011-09-07 株式会社·R-技术上野 含有噻唑衍生物的含水组合物
CA2575411A1 (en) 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
CA2579889A1 (en) 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
TW200835687A (en) * 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
EP2172221A4 (en) 2007-06-25 2010-06-23 R Tech Ueno Ltd COMPOSITION FOR OPHTHALMIC DISEASE ASSOCIATED WITH HYPOXIA OR ISCHEMIA
JPWO2009051223A1 (ja) 2007-10-19 2011-03-03 株式会社アールテック・ウエノ 白内障処置のための医薬組成物

Also Published As

Publication number Publication date
CN101932568B (zh) 2014-08-06
JP2011510911A (ja) 2011-04-07
TW200934488A (en) 2009-08-16
ES2452834T3 (es) 2014-04-02
EP2252604A1 (en) 2010-11-24
AU2009209885A1 (en) 2009-08-06
CA2712962A1 (en) 2009-08-06
US8507690B2 (en) 2013-08-13
ES2527014T3 (es) 2015-01-19
EP2650287B9 (en) 2015-08-05
JP5415430B2 (ja) 2014-02-12
EP2639229A2 (en) 2013-09-18
EP2650287B1 (en) 2014-12-03
DK2639229T3 (da) 2015-02-02
RU2010136301A (ru) 2012-03-10
CN101932568A (zh) 2010-12-29
EP2639229B9 (en) 2015-08-05
KR20100112623A (ko) 2010-10-19
EP2639229B1 (en) 2014-11-26
AR070336A1 (es) 2010-03-31
RU2496776C9 (ru) 2014-12-20
CA2712962C (en) 2016-08-16
EP2650287A1 (en) 2013-10-16
AU2009209885B2 (en) 2013-12-05
HK1152293A1 (en) 2012-02-24
KR101622414B1 (ko) 2016-05-18
MX2010008460A (es) 2010-08-30
EP2676955A1 (en) 2013-12-25
NZ587205A (en) 2012-06-29
EP2676955B1 (en) 2015-03-11
TWI437986B (zh) 2014-05-21
EP2639229A3 (en) 2013-12-25
EP2252604B1 (en) 2014-01-08
WO2009096609A1 (en) 2009-08-06
BRPI0906352A2 (pt) 2015-07-07
HK1185348A1 (en) 2014-02-14
RU2496776C2 (ru) 2013-10-27
US20110015240A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
HK1185348A1 (en) Thiazole derivative and use thereof as vap-1 inhibitor vap-1
HK1210612A1 (en) Benzene or thiophene derivative and use thereof as vap-1 inhibitor vap-1
HK1254895A1 (zh) 苄基苯衍生物及使用方法
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (en) Compounds and methods of use
IL210055A0 (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
IL192634A0 (en) Thiazoles as 11 beta-hsd1 inhibitors
ZA201003596B (en) Haloallylamine inhibitors of ssao/vap-1 and uses thereof
EP2264017A4 (en) Heterocyclic derivative and its use
EP2383263A4 (en) NEW THIAZOLIDINEDIONE DERIVATIVE AND ITS APPLICATIONS
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
GB0812031D0 (en) Thiazole derivatives
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
HK1149933A1 (en) Diazacarbazoles and methods of use
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
IL209548A0 (en) Diazacarbazoles and methods of use
EP2231625A4 (en) KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE
IL208771A0 (en) Iminopyridine derivatives and use thereof
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
ZA200907727B (en) Cinnamaldehyde formulations and methods of use
IL208824A0 (en) Iminopyridine derivative and use thereof
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
HK1167406A1 (en) Pyrazolone-derivatives and their use as pd4 inhibitors pd4